Related Experiment Video
Updated: May 2, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.6K
Refractory atrial fibrillation effectively treated with ranolazine
Aditi Vaishnav1, Avani Vaishnav1, Yash Lokhandwala2
1Medical Student, Dr. D.Y. Patil Medical College, Navi Mumbai, India.
Indian Heart Journal
|March 4, 2014
Summary
Ranolazine offers a new treatment option for patients with atrial fibrillation refractory to amiodarone. This medication selectively targets sodium channels, successfully managing highly symptomatic cases.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Atrial fibrillation is a common cardiac arrhythmia requiring effective management.
- Current therapies focus on rhythm and rate control medications.
Observation:
- Amiodarone-refractory atrial fibrillation presents significant management challenges.
- Two highly symptomatic patients with refractory atrial fibrillation were treated.
Findings:
- Ranolazine, a selective Na+ channel blocker, was administered.
- This approach successfully delayed atrial depolarization and managed symptoms.
Implications:
- Ranolazine represents a potential novel therapeutic strategy for difficult-to-treat atrial fibrillation.
- Further research into ranolazine's efficacy and safety in larger cohorts is warranted.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
01:25Dysrhythmias VI: Management of Dysrhythmias
597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
1.2K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.2K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K